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BCCSkin homeostasis is maintained, in part, through regulation of gene expression orchestrated by type
II nuclear hormone receptors in a cell and context speciﬁc manner. This group of transcriptional
regulators is implicated in various cellular processes including epidermal proliferation, differentia-
tion, permeability barrier formation, follicular cycling and inﬂammatory responses. Endogenous
ligands for the receptors regulate actions during skin development and maintenance of tissue
homeostasis. Type II nuclear receptor signaling is also important for cellular crosstalk between mul-
tiple cell types in the skin. Overall, these nuclear receptors are critical players in keratinocyte and
melanocyte biology and present targets for cutaneous disease management.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. Open access under 1. Mechanisms of action for type II nuclear receptors
Transcriptional control of gene expression is achieved, in part,
through protein factors bound to regulatory elements present on
the chromatin. The type II nuclear receptors (NR), belonging to
the superfamily of steroid-thyroid hormone nuclear receptors, con-
tribute to the cellular responses of physiological demands [1–4].
Transcriptional modulation is achieved by structural adjustments
initiated through ligand binding. Present throughout the animal
kingdom, this family of environmental sensors contributes both
positively and negatively to gene expression. This differential reg-
ulation is useful in organismal development and homeostasis,
though it is also implicated in a variety of pathological conditions.
The present review will only detail the contributions of type II NRs
towards epidermal and follicular development and homeostasis,and in skin diseases. Particular emphasis is given on melanocyte
biology and in melanomagenesis arising from altered signaling be-
tween keratinocytes and melanocytes, while highlighting the po-
tential therapeutic value of these pliable receptors.
Type II NRs belong to a larger family of steroid hormone recep-
tors, all sharing similarities in domain structure (Fig. 1) [5,6]. Dis-
tinct variations in domain sequence has allowed for the
diversiﬁcation and specialization currently present within the fam-
ily [7]. The DNA binding domain is highly conserved across the
family and contains two zinc ﬁnger motifs. These domains recog-
nize and bind short response elements, allowing for both homo-
and hetero-dimerization combinations. Two activation domains
called AF-1 and AF-2 assist the receptors in dimerization and
DNA binding. Variability is more evident within the carboxyl ter-
minal ligand binding domain, where individual receptors have
evolved to bind a variety of signaling molecules [8]. Receptors for
which ligand speciﬁcity has yet to be determined are labeled as or-
phan receptors. Endogenous ligands for NRs known to be ex-
pressed in skin include: all-trans retinoic acid (RA) and 9-cis RA
for retinoic acid receptor (RAR) [9,10], 9-cis RA for retinoid-X-
AF-1 DBD LBD AF-2HN C
Fig. 1. Schematic representation of functional domains in type II nuclear receptors.
Transcriptional activation function 1 (AF-1) domain initiates at the amino terminus,
followed by the DNA-binding domain (DBD). A ﬂexible hinge region (H) assists in
DNA binding, dimerization and transactivation functions. Variable ligand-binding
domains (LBD) and a second activation function (AF-2) are present at the carboxyl
terminus.
530 S. Hyter, A.K. Indra / FEBS Letters 587 (2013) 529–541receptor (RXR) [2,11], 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3)
for vitamin D receptor (VDR) [12], fatty acids/lipids for peroxisome
proliferator-activated receptor (PPAR) [13–16], oxysterols for liver
X receptor (LXR) [17] and triiodothyronine for thyroid receptor
(TR) [18].
A distinguishing feature of type II NRs is the promiscuity dis-
played by RXR. All NRs from this class form heterodimers with
an isoform of RXR (a/b/c) and regulate gene expression in a ligand
dependent fashion. RXRa is able to heterodimerize with some 15
NR family members and occupy direct repeat response elements
present on the promoters of target genes [19–23]. The nonsteroidal
ligands of RXR/NR heterodimers dictate the organization of com-
plexes associated with the receptors. Serial combinations of regu-
latory proteins allow chromatin remodeling and recruitment of
basal factors to initiate and/or repress transactivation (Fig. 2)
[24,25]. Coactivators include ATP-dependent chromatin remodel-
ers, histone acetyltrasferases and the Mediator complex [26–30].
Corepressors comprise the N-CoR/SMRT assembly and histone
deacetylases [31–34]. The large numbers of regulatory factors, as
well as tissue speciﬁc localization, allow NRs to inﬂuence a diverse
range of gene expression in a cell and tissue speciﬁc manner. For
example, the PPARc cofactor PGC-1 is present in adipose tissue
but not ﬁbroblasts, allowing a cell-type speciﬁc activation of genes
related to adaptive thermogenesis [35]. Post-translational modiﬁ-
cations of co-factors such as phosphorylation, methylation, sumoy-
lation and ubiquitination are also known to contribute to the
extensive speciﬁcity of NR regulation [36].2. Skin morphogenesis, epidermal homeostasis and hair cycling
Skin is the largest organ in the body and is comprised of multi-
ple cell types such as epidermal keratinocytes, dermal ﬁbroblasts
and hypodermal adipocytes, besides Langerhans cells, melanocytes
and endothelial cells. It utilizes both autocrine and paracrine sig-
naling for development and maintenance of tissue homeostasisLBD
DBD
NRRE NRRE
LBD
DBD
TSS
X
Repression
NCoR/SMRT
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Fig. 2. Putative mechanisms of transcriptional regulation by type II nuclear receptors. R
with co-repressor protein complexes, including NCoR/SMRT and histone deacetylases
complexes are replaced by co-activator proteins such as ATP-dependant chromatin rem
DBD, DNA-binding domain; LBD, ligand-binding domain; NRRE, nuclear receptor respon[37]. The outermost epidermal layer provides a protective barrier
to environmental and physical stresses and constantly progresses
through cycles of proliferation and differentiation. Basal keratino-
cytes located on the innermost epidermal basement membrane
(separating epidermis from the underlying dermis) generate
daughter cells, which undergo committed differentiation that give
rise to ordered layers of suprabasal early- and late-differentiated
keratinocytes. Appendages such as hair follicles and sebaceous
glands (SGs) are invaginated into the mesenchymal-derived der-
mal layer. Different resident multipotent skin stem cell (SC) niches
contribute to the renewal, maintenance and repair of the epider-
mal tissues of the skin, including interfollicular epidermis (IFE),
hair follicles and SGs [38]. Epidermal SCs play a crucial role in
maintaining tissue homeostasis by supplying new daughter cells
to replace those constantly lost during turnover or following in-
jury. Bulge SCs are known to maintain normal follicle homeostasis
and can also contribute to the formation of IFE following skin in-
jury and during wound healing. Melanocytes are also located with-
in the hair follicles where they primarily contribute pigmentation
to coat color. In humans, IFE melanocyte populations rely on kera-
tinocytic paracrine signaling for assistance in photoprotection from
solar ultraviolet irradiation [39].
Type II nuclear receptor signaling contributes to the perpetual
renewal of keratinocytic layers, maintenance of the epidermal per-
meability barrier (EPB) and follicular cycling. Impaired expression
or function of these receptors is implicated in aberrant prolifera-
tion and/or differentiation of epidermal tissue and alopecia (hair
loss). The promiscuous role that RXRs play in type II NR signaling
hints to the impact that impaired RXR expression or activity inﬂu-
ences receptor signal transduction. Although many of RXRs hetero-
dimer partners are implicated in a wide variety of skin diseases, in
many cases these pathologies could instead be associated with
compromised RXR mediated gene regulation. Regardless, only
studies that have speciﬁcally indicated a speciﬁc role for RXR func-
tion will be discussed here. RXRs play a critical and varied role in
epidermal differentiation and EPB maintenance. RXRa, the primary
isoform in skin and hair follicles, has stronger expression levels
compared to RARs, and RXRa/RARc heterodimer appears to be
the major retinoid transducing element in epidermal biology
[40–42]. RXRa/RARc heterodimerizationis also critical in the
development and formation of epidermal lamellar granules by
repression of target genes, as RARc agonists promote lamellar
granule defects in murine skin. Similarly, RXRa/PPARbd heterodi-
mers are equally important to stratum corneum homeostasis
through activation of gene transcription [43].LBD
DBD
NRRE NRRE
LBD
DBD
TSS
Activation
ADCR HAT
MC
epression of gene expression by nuclear receptor heterodimers involves association
(HDAC). Positive transactivation occurs after ligand binding when co-repressor
odelers (ADCR), histone acetyltransferases (HAT) and the Mediator complex (MC).
se element; TSS, transcriptional start site.
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sis has long been observed. Although, comprehensive studies have
investigated multiple proteins along this pathway in skin (such as
retinoic acid binding proteins), this review will focus primarily on
RARs in human and rodent skin, particularly the role of RARc
[40,44]. RA is widely used as a therapeutic against various skin dis-
eases due to its inhibitory effects on keratinocytic terminal differ-
entiation, besides regulating keratinocyte proliferation and
apoptosis, through modulation of RAR target genes [45]. Manage-
ment of keratin expression, which in turn dictates status of epider-
mal differentiation, is a known regulatory mechanism of cutaneous
RARs [46–48]. Unfortunately, the use of pan-retinoids is limited
due to unwanted side effects such as skin irritation, hypertriglycer-
idemia, bone toxicity and teratogenicity [49,50]. In order to utilize
these efﬁcacious compounds in a dermatological setting, receptor-
selective retinoids in parallel with prophylactic lipid management
therapies may provide clinical beneﬁts with decreased risk of
toxicities.
Early studies have elucidated the synthesis of pre-hormone 25-
hydroxycholecalciferol (calcifediol) by murine epidermal basal
cells that acts in a paracrine manner for the CYP27B1 and VDR
expressing differentiated keratinocytes [51]. Typical of the type II
nuclear receptors, 1,25(OH)2D3-induced VDR activation inhibited
proliferation and promoted differentiation of keratinocytes, though
VDR/RXRa heterodimers can transactivate keratinocytic genes
independent of 1,25(OH)2D3 binding [52]. DeltaNp63alpha, a criti-
cal regulator of epidermal biology, is known to directly control VDR
expression in murine skin and mediate its function in a ligand-
independent manner [53]. Mice bearing a targeted ablation of
VDR present a large number of pathological properties in the skin,
including progressive alopecia and dermal cysts as well as de-
creased expression of epidermal differentiation markers [54,55].
By expressing in discrete epidermal locations, VDR-interacting
coactivators contributed divergent roles towards keratinocyte pro-
liferation and differentiation [56,57]. VDR and its associated cofac-
tors also contributed to lipid production and epidermal barrier
formation. Genetic network analysis has implicated VDR as a nec-
essary regulator of skin barrier formation and predicts the pheno-
type characterized in the VDR-null mice [58]. Many epidermal
genes induced by WNT/b-catenin contain VDR response elements
and were activated independently of TCF/LEF, implying that it is
part of a TCF/LEF-independent aspect of WNT signaling [59]. Like-
wise, depletion of follicular keratinocyte populations in VDR-null
mice was linked to aberration of the canonical WNT pathway [60].
Alopecia is a commonplace in hereditary resistance to
1,25(OH)2D3 and VDR expression is seen in the outer root sheath
keratinocytes and dermal papilla of follicles, increasing during late
anagen and catagen [61]. The transcriptional repressor hairless
(HR) co-localized with VDR in the outer root sheath of hair and
has been shown to inhibit target genes leading to hair cycle pro-
gression [62]. Another VDR cofactor and critical subunit of the
transcriptional coactivator complex Mediator (MED), MED1, has
been recently linked to hair cycling and epidermal proliferation
and differentiation. Selective ablation of MED1 in keratinocytes
presents a similar phenotype to VDR or HR ablation [63]. miR-
125b is a known repressor of skin differentiation in the bulge re-
gion of the hair follicle and expressing miR-125b in SC progeny sig-
niﬁcantly downregulated VDR activity [64].
PPARbd expression was seen in both basal and suprabasal layers
of the normal human epidermis, while PPARa and PPARc expres-
sion was conﬁned to suprabasal epidermal cells and was linked
to squamous differentiation [65]. PPARs are transcriptionally regu-
lated by AP-1, C/EBP family members and p63, the master regula-
tor of epidermal morphogenesis and differentiation [66,67].
Mechanistically, inhibition of the PKC/MAPK pathway through
PPAR-mediated PKCa-ubiqutitination has been implicated inreduction of epidermal proliferation [68]. All PPAR isoforms were
expressed in human hair follicle cells while PPARc ablation in mice
mimicked a human scarring alopecia phenotype [69,70].
The ability of LXRs to act as environmental cholesterol sensors
enables them to contribute to consistent epidermal turnover which
support a sound EPB. LXRab are expressed in all layers of the hu-
man epidermis, as well as in the outer root sheath and SG, and
the LXR agonists oxysterols act on epidermal keratinocytes by
reducing proliferation and inducing differentiation [71]. One pro-
posed mechanism of LXR mediated induction of keratinocytic dif-
ferentiation is inﬂuencing the binding of transcriptional complex
AP-1 to target genes. ChIP-on-chip studies investigating LXRb/
RXRa binding in human keratinocytes revealed a strong correlation
to AP-1 response elements, with up to 77% of all LXRb/RXRabind-
ing sites associated with AP-1 motifs [72]. This could indicate LXR
involvement in the pathogenesis of certain diseases that present
with abnormal keratinocytic differentiation and/or compromised
barrier function.
Thyroid-stimulating hormone receptor signaling is commonly
associated with cutaneous biology, though TR ligand binding is
also known to contribute to epidermal homeostasis. Resistance to
thyroid hormones is a syndrome with a wide variety of symptoms
and is connected to TRb mutations in both mice and humans
[73,74]. Follicular TRb is the predominant isoform expressed with-
in human skin and one phenotype of the disease linked to aberrant
TRb signaling is alopecia [75,76]. In support of a role for TRb in hair
cycle homeostasis, thyroid hormones and TRb-selective thyromi-
metics are able to induce hair growth in both murine and simian
models, as well as stimulate intrafollicular melanin production
[77,78]. TRs bind to conserved keratin response elements located
in the promoter region of epidermal keratin genes and can directly
control their transcription. One proposed mechanism of these
genes involves transcriptional repression in the presence of a li-
ganded TR receptor. In this scenario, proteins typically seen as
components of a co-activator/histone acetylase complex display
repressive tendencies in the presence of liganded receptors while
co-repressors act as activators when unliganded TRs are present
on the keratin response element [79]. Transcriptome analyses from
epidermal keratinocytes treated with either thyroid hormone or
vehicle display only a small number of genes that are differentially
expressed. Among the suppressed genes (integrin b4, plectin, colla-
gen XVII, MMP1/3/14) there was signiﬁcant association to the blis-
tering skin disease epidermolysis bullosa, implying an inhibitory
role of thyroid signaling to extracellular matrix maintenance [80].
3. Inﬂammatory skin diseases
Cutaneous inﬂammatory disorders are characterized by inﬂam-
mation of the skin that can lead to patient discomfort or disﬁgure-
ment. Psoriasis is a genetic-based cutaneous syndrome that
involves epidermal hyperproliferation, compromised EPB and an
inﬁltrative immune response. It is present in up to 5% of the pop-
ulation, affects both sexes equally and is able to manifest within
the ﬁrst two decades of life [81]. As it is currently incurable, pri-
mary treatment options focus on the control of symptoms and in-
clude the use of topical corticosteroids, phototherapy and
moisturizing creams [82]. As proof of concept that type II NR acti-
vation is a feasible therapeutic approach, acitretin and calcipotriol
are widely utilized for psoriasis. Atopic dermatitis (AD) is another
chronic inﬂammatory skin disease that is characterized by dry and
itchy skin, persistent infections and very early onset [83]. AD is
linked to other atopic diseases such as asthma and allergic rhinitis,
and defective EPB function, environmental insults or genetic back-
ground are predisposing factors for this heterogeneous disease
[84,85]. Treatment options are similar to those for psoriasis, while
preventing future allergic reactions is also important. Unfortu-
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immune functions to be eradicated. Due to early onset and lifelong
activity, the use of chronic corticosteroid therapy is discouraged.
Knowledge regarding transcriptional regulation by key factors of
EPB and epidermal proliferation gene networks enhances our reti-
nue of therapeutic strategies in these diseases. NR ligands may be
useful to modulate multiple pathways in order to lessen side ef-
fects and/or concentrations of the more efﬁcacious compounds.
Mice with an epidermal-speciﬁc ablation of RXRa (RXRaep/)
presented epidermal hyperplasia, alopecia, dermal cysts and a
cutaneous inﬂammatory response [86,87]. Likewise, mice lacking
both RXRa and RXRb in keratinocytes (RXRa/bep/) developed a
chronic dermatitis similar to human AD patients, elevated serum
IgE/IgG and cytokine production associated with Th2-type re-
sponse. Importantly, thymic stromal lymphopoietin (TSLP) was
strongly upregulated from the basal keratinocytes, potentially
inﬂuencing the systemic AD phenotype in these mice [88]. To fur-
ther support the hypothesis that loss of RXRa contributed to a
derepressive mechanism on gene expression leading to inﬂamma-
tory responses, expression of RXRa has been reported to decrease
in human psoriatic lesions, with levels in progressive disease fur-
ther reduced compared to stable stages [89].
Use of the anti-proliferative, pro-differentiative properties of
1,25(OH)2D3 is not ideal due to harmful calcemic effects. Therefore,
synthetic deltanoids represent the best way to initiate VDR activa-
tion for therapeutic or investigative purposes. It was previously
discussed that keratinocytic RXRab ablation upregulates produc-
tion of TSLP leading to an AD-like phenotype in the mouse. Inter-
estingly, topical application of deltanoids also induces TSLP in
epidermal keratinocytes, suggesting the role of RXR/VDR heterodi-
mers in regulating TSLP expression in this cell type. That evidence
suggests a role for VDR antagonists in the treatment of human AD
patients [90]. Conversely, deltanoids were shown to signiﬁcantly
improve allergen-triggered eczema in a mouse model through
increasing populations of FOXP3-expressing regulatory T cells
[91]. Further evidences are needed to determine how VDR transac-
tivation can initiate anti-inﬂammatory mechanisms if deltanoids
are to become accepted therapy for hyperproliferative epidermal
disorders in the clinic.
The anti-inﬂammatory actions of PPARa offer additional treat-
ment modalities for reoccurring skin conditions such as AD and
psoriasis. Stimulation of epidermal differentiation and reduction
of proliferation can potentially treat these conditions without se-
vere side effects brought on by glucocorticoids (GC). PPARa/
mice (with a germline deletion of the Ppara gene) subjected to
antigen sensitization exhibit increased epidermal thickening and
inﬂammatory responses compared to wild-type controls, poten-
tially through the loss of IL-2-mediated induction of Treg popula-
tions [92]. PPARa/ skin also display heightened levels of both
Th2- and Th1-related responses, as well as enhanced NF-jB signal-
ing. Furthermore, PPARa expression is downregulated in lesional
skin of human AD patients compared to non-atopic individuals
[93]. Topical application of PPARa agonists reduces the hyperplas-
tic response in mouse skin brought on by TPA treatment, in part
through the reduction of inﬂammatory cytokines. Similar results
were seen in oxazolone (OX)-induced allergic dermatitis mouse
models, and importantly, combination therapy of PPARa agonists
and GCs for severe dermatitis prevented GC-induced side effects
and inhibited rebound ﬂares [94,95]. Conversely, activation of
PPARbd may trigger psoriasis pathogenesis within the skin and
treatment strategies may include antagonism of this signaling
pathway. PPARbd is upregulated at both the mRNA and protein le-
vel in psoriatic lesions compared to nonlesional skin in human pa-
tients and eicosanoid accumulations within the lesions can
activate PPARbd [96,97]. Also, topical antagonists targeted to cuta-
neous PPARbd demonstrated efﬁcacy in a psoriatic mouse model[98]. Alongside other physiological defects, PPARbd-null mice exhi-
bit an elevated epidermal hyperplastic response after TPA adminis-
tration and delayed barrier recovery following acute barrier
disruption [99,100]. An increase in the release of inﬂammatory
cytokines after wound healing in murine skin requires upregula-
tion of PPARbd that is otherwise undetected in normal skin. Inter-
estingly, this pro-inﬂammatory cascade initiates production of
endogenous PPARbd ligands, reinforcing the activation of PPARbd
after skin injury [101,102]. PPARbd is also linked to UV-induced
premature senescence via upregulation of PTEN that attenuates
reactive oxygen species in keratinocytes [103]. Likewise, epidermal
PPARc signaling is also a target for the UV-induced inﬂammatory
response. UV irradiation of human keratinocytes produces potent
PPARc agonistic activity and enhances COX-2 expression in these
cells. Furthermore, PPARc activation was seen as a general conse-
quence to various oxidative stressors in human sebocytes
[104,105].
An increased accessibility of environmental antigens through
epidermal tissue can activate cutaneous immune responses that
potentially drive inﬂammation. Creation and maintenance of the
EPB is a multistep process involving lipid production and lamellar
body formation and LXR activation appears to hold key functions in
many of these stages [106,107]. EPB function is tightly linked to
cholesterol levels in the epidermis and LXR has been shown to reg-
ulate the storage and efﬂux of lipid species. Members of the ATP-
binding cassette transporter family such as ABCA1, ABCA12 and
ABCG1, as well as the glycerol channel AQP3, are transcriptionally
regulated by oxysterols [108–111]. Environmental toxins present
in cigarette smoke have been linked to several skin diseases includ-
ing psoriasis and melanoma [112,113]. Translocation of LXR to the
nucleus in HaCaT cells after exposure to cigarette smoke facilitated
an increase in cholesterol trafﬁcking as a result of increased ABCA1
expression [114]. The ability of the synthetic LXR agonist T1317 to
prevent physical changes inherent to photoaging and chronological
skin aging has been investigated. T1317 inhibited the expression of
cytokines and metalloproteinases in cell-based models of skin
aging. Furthermore, LXRb-null murine skin mimics some of the
characteristics seen in chronologically aged human skin and the
topically applied agonist reduced UV-induced skin thickness and
wrinkle formation in a mouse model [115].
The anti-inﬂammatory actions of LXR activators have been
demonstrated in both irritant and oxazolone (OX)-induced allergic
dermatitis mouse models, in part through the inhibition of proin-
ﬂammatory cytokines that are speciﬁc to LXRb [116,117]. Similarly,
global gene expression studies using primary human keratinocytes
from psoriatic lesions, non-affected skin of the same patients and
healthy control subjects, indicates a role for LXRa in regulating
inﬂammatory response. Along the same line, knocking down LXRa
in human keratinocytes lead to a genomic proﬁle similar to that
seen in psoriatic skin lesions [118]. Even if LXRs are not directly in-
volved in disease pathogenesis, the receptors might still be utilized
as therapeutic tools to modulate cellular lipid levels. For example, a
human sebaceous cell line treated with LXRa agonists increased li-
pid synthesis and induced the lipogenic gene SREBP-1, potentially
useful for the treatment of seborrhea and acne [119]. Selective LXR
agonists that are isoform and tissue-speciﬁc could provide local-
ized and speciﬁc cutaneous effects that do not inﬂuence other
LXR receptor pools [120,121].
4. Epidermal carcinogenesis
Non-melanoma skin cancers arise from both the basal and
squamous cells of the epidermis. Basal cell carcinoma (BCC) is
the most common neoplasm related to the Caucasian population
and its incidence rate is increasing yearly [122]. Though considered
malignant due to its ability to invade deep into tissue, it rarely
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skin disposed to freckling, family history of BCC and exposure to
ultraviolet radiation. Patients with BCC also tend to be prone to
other types of skin cancer including malignant melanoma [123].
Disease progression typically arises from UV-induced actinic kera-
tosis or mutations in the hedgehog signaling pathway. Surgical
excision is the treatment of choice though pathway speciﬁc com-
pounds such as vismodegib provide additional therapy options
[124]. Cutaneous squamous cell carcinoma (SCC) is the second
leading cause of skin cancer, yet unlike BCC it tends to exhibit met-
astatic behavior [125]. Again, exposure to ultraviolet radiation is
the predominant risk factor for this disease, though immunosup-
pressed patients are at increased risk for metastatic spread [126].
Treatment options include surgical removal, radiation therapy
and in certain cases chemotherapeutics such as 5-ﬂuorouracil or
imiquimod [127]. Investigations into pathways regulating keratin-
ocytic proliferation and differentiation may lead to additional
treatment options useful in treating these disﬁguring diseases.
The transcription factor KLF4 is required for proper EPB forma-
tion in mice and dysregulated KLF4 activity is shown to be onco-
genic [128]. KLF4 regulates expression of RXRa and KLF4-induced
malignant transformation is sensitive to retinoids in vitro. Impor-
tantly, rexinoid application drastically prevented formation of
SCC in a KLF4-activated transgenic mouse line [129]. These results
suggest existence of a crosstalk between RXR and KLF4 signaling,
where KLF4-mediated expression of RXRa contributes to tumor
suppressor activity within the epidermis. RXRaep/ mice, selec-
tively lacking RXRa in epidermal keratinocytes, subjected to a
7,12-dimethylbenz(a)anthracene (DMBA)/12-O-tetradecanolyph-
oral-13-acetate (TPA) induced two-step chemical carcinogenic pro-
tocol developed higher numbers of epidermal tumors compared to
control mice [130]. The RXRaep/ papillomas progressed towards
SCC in a murine model, further validating the role of RXRa as a
cutaneous tumor suppressor.
Both keratinocytes and melanocytes downregulated expression
of RARs when subjected to UV exposure, potentially initiating cel-
lular responses to ionizing radiation through the removal of
repressive transcriptional controls [131–133]. A similar downregu-
lation of RAR in mouse skin was seen after application of TPA, as
well as when normal human skin progresses through premalignant
actinic keratosis to invasive SCC [134–136]. A loss of RARc expres-
sion exacerbated carcinogenic effects of tumor promoters and en-
hances malignant transformation [137,138]. Topical application of
RA during the promotion stage of carcinogen treatment in mice re-
duced the yield of papilloma and carcinoma formation [139]. Like-
wise, the RARbc retinoid tazarotene displayed anti-tumoral
activity when topically applied to BCC and may inhibit psoriatic
proinﬂammatory gene networks [140–142]. Above results indicate
important roles of retinoids and retinoid receptors in the control of
epidermal homeostasis and prevention of hyper-proliferative dis-
eases and skin cancer.
The regulatory nature of VDR in hair cycle progression and bar-
rier formation is critical to maintain skin homeostasis, therefore
defects in the transactivating function of the receptor allow path-
ological conditions to manifest. Multiple VDR polymorphisms have
been associated with a broad spectrum of cutaneous disease,
including SCC, BCC and vitiligo [143–148]. Indeed, inactivation of
VDR in mice enhanced sensitivity to both chemical and solar-in-
duced skin carcinogenesis, potentially through activation of the
hedgehog pathway [149,150].
Due to evidence of PPAR signaling in the development of aber-
rant growths in differing tissue types, studies have investigated the
role of these receptors in cutaneous neoplasms. Tumor formation
and size were increased after chemical carcinogen application in
PPARbd/ mice, while those selectively lacking PPARc in epider-
mal keratinocytes show an increase in benign tumors, SCC andBCCs [130,151]. Ligand activation of PPARbd inhibits chemically in-
duced skin tumorigenesis, most likely through induction of kera-
tinocytic differentiation, and the addition of COX-2 inhibitors
may result in synergistic efﬁcacy [152,153].
In mice, TRb expression is detected in normal and TPA-treated
hyperplastic skin. Loss of TRb expression is seen in benign papillo-
mas generated by the DMBA/TPA protocol and completely abro-
gated in subsequent SCC formation. Importantly, skin tumors
from mice lacking both TRa/b were more likely to develop in situ
carcinoma and SCC than those from wildtype mice, supporting
TRs role as a tumor suppressor [154]. In order to determine the role
TRs have in the hyperproliferative response, TRab-double null
mice were subjected to both TPA and RA treatments [155,156]. Re-
duced hyperplasia with a decreased expression of cyclin D1 was
seen in the TRab skin after TPA treatment. That proﬁle was corre-
lated with increases in cell cycle inhibitors p19 and p27, as well as
induction of proinﬂammatory cytokines and phosphorylation of
p65/NF-jB and STAT3. This phenotype is opposite to that seen in
PPARbd/ mice and elucidates the combinatorial mechanisms
RXR/NR heterodimers regulate within the skin. Similarly, a typical
retinoid response requires the presence of ligand-bound TR in
mouse skin. Decreases in skin hyperplasia and expression of kera-
tins 5/6, alongside increased transcription of inﬂammatory and
chemotactic cytokines, are also seen in TRa/b/mice treated with
9-cis RA. Since TPA and retinoids are modulating separate signaling
cascades, it is possible that TRs are involved in the cellular re-
sponses to both these compounds.5. Melanocyte homeostasis and melanomagenesis
Melanocytes are neural crest-derived pigment producing cells
that contribute photoprotective properties to the skin. Cutaneous
melanoma is the deadliest form of skin cancer, with a diagnosis
of metastasis indicating a median survival rate of less than a
year [157]. Solar ultraviolet irradiation, especially childhood
sun exposure, is an important etiological risk factor of melanoma
[158]. Surgical excision prevents growth of the primary lesion,
yet once transformed melanocytes spread to distal organs and
this disease is refractory to current therapeutics. Recent evidence
supports the use of MAPK inhibitors and immunomodulatory
treatments with the goal of increasing lifespan [159,160]. There-
fore, any research directed towards key regulators of melanocy-
tic activity could potentially open up new avenues for disease
management.
Type II NR-mediated signaling via RXR dimerization is essential
to melanocyte biology. RXRa/b expression has been detected in
B16 and S91 murine melanoma cells, with RXRb being the predom-
inant isoform [161,162]. Interestingly, loss of melanocytic RXRa
expression was seen in human primary and metastatic melanoma
compared to benign nevi, indicating the importance of this signal-
ing pathway to the differentiation of these cell types [163]. RARb
expression was also downregulated in melanoma and its
RA-induced expression was linked to growth inhibition and differ-
entiation in these cells. Sequential occupation of the RA response
element located on the Rarb promoter by RXR/RXR and RXR/RAR
combinations is believed to be a molecular switch responsible for
Rarb transcriptional activation in these cells. Since ligand activa-
tion of RXR heterodimeric partners regulates transcriptional activ-
ity of target genes involved with differentiation and growth arrest,
it is possible that combinatorial activation of both dimer partners
may assist in melanoma therapy. Rexinoid treatment alongside
glitazones (PPARc agonists) have displayed efﬁcacy against mel-
anomagenesis in in vitro and xenograft models, potentially
through the inhibition of matrix metalloproteases and increases
in S100A2 calcium binding activity [164–166].
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in manipulating melanocyte activation and proliferation through
modulation of the cutaneous microenvironment [167]. RXRa/NR
heterodimer binding regulates transcriptional repression of soluble
mitogens and cytokines, making it a critical factor in the ultraviolet
radiation (UVR) induced cellular responses. The loss of keratinocy-
tic RXRa in RXRaep/mice relieves transcriptional repression and
allows overexpression of keratinocytic soluble factors that act on
melanocytic cell-surface receptors. Higher numbers of epidermal
melanocytes were seen after UVR exposure in RXRaep/ mice
compared to controls, suggesting contribution of soluble factors
in the cellular microenvironment for melanocyte activation and
migration out of the hair follicle. Indeed, increased expression of
Edn1, Fgf2 and Kitlg, that are known to be upregulated by keratino-
cytes and inﬂuence melanocyte activation, migration and prolifer-
ation, were seen in RXRaep/ skin post-UVR [167]. Interestingly,
in a two-step carcinogenesis model, RXRaep/ mice developed a
higher number of dermal melanocytic growths (nevi) compared
to control mice, implicating contribution of keratinocyte-derived
factors in melanomagenesis. Only nevi from RXRa mutant mice
progressed to melanoma-like tumors, suggesting that RXRa-medi-
ated distinct non-cell autonomous actions suppressed nevi forma-
tion and melanoma progression in mice [130]. Similarly, VDR/
mice undergoing identical treatments also developed higher num-
bers of melanocytic lesions, indicating RXRa/VDR heterodimeriza-
tion may be the causative factors, at least in part, in these non-cell
autonomous events [130]. Finally, the loss of keratinocytic RXRa
alongside an activated-CDK4 mutation enhanced the metastatic
transformation of cutaneous melanoma after chemical carcinogen-
esis. Expression of Edn1, Hgf, Fgf2, Pomc and Kitlg were all upregu-
lated in the skin of RXRaep//CDK4R24C/R24C bigenic mice. Direct
binding of RXRa on the promoter of Edn1 and Hgf was also seen
in ex vivo primary murine keratinocytes. Gene expression analyses
on mRNA isolated from melanocytic lesions from the bigenic skin
using laser-capture microdissection demonstrated reduced apop-
totic and enhanced invasive responses within bigenic melanomas.
Loss of epidermal RXRawas also seen in human melanoma pro-
gression and could potentially be utilized as a therapeutic bio-
marker [168]. These results indicated a crucial role of RXRa/NR
signaling in melanocytic homeostasis and in cellular responses to
tumor promotion.
All RAR isoforms were expressed in melanocytes and treatment
of retinoids, particularly RARc-speciﬁc agonists, inhibits growth
and initiates apoptosis in melanoma cells [169–171]. RA treatment
increases expression of RARb and PKCa while stimulating AP-1
transcriptional activity in melanoma cells. RARa speciﬁc agonists
were most effective in upregulating RARb levels and combinatorial
RAR/RXR activation demonstrate the strongest induction of both
PKCa and AP-1 function in murine melanoma cells [172–174]. Loss
of RARs, especially RARb and its tumor suppressor activities, was
observed during melanomagenesis and could account for RA resis-
tance in this disease [163,175,176]. That disruption of RARb or
RARc signaling in benign nevi may predispose a lesion towards
malignant transformation. Co-treatment of retinoids with histone
deacetylases also counteracted the epigenetic silencing of RARb of-
ten seen in RA resistant melanoma cell lines and provides in-
creased antitumor activity [177]. Another mechanism implicated
in RA-resistant melanoma cells is an increase in intracellular reac-
tive oxygen species (ROS) that is inversely related to RAR activity.
RA-sensitivity was restored when ROS levels were lowered, poten-
tially through improved RXR/RAR promoter binding activity [178].
RA treatment in combination with polyl:C synergistically increased
the toll-like receptor 3 chemokine responses in human melanoma
cells and induced migration of antigen-presenting cells [179]. De-
creased expression of collagenolytic-enzymes and alterations in
mobility-associated cell surface receptors were consequences ofRAR activation in melanoma cells [180,181]. Further evidence of
RARc-mediated inhibition of melanoma invasion came from
microarray analysis of murine melanoma cells treated with RARc
agonists, which identiﬁed the sulfotransferase CHST10 as being di-
rectly regulated by RARc through RA response elements located in
its promoter region. CHST10 synthesizes a HNK-1 carbohydrate
that was involved with cell adhesion in the nervous system and
RA-mediated embryonic plasticity [182]. Altogether, RAR-speciﬁc
agonists present a potential therapeutic candidate for the treat-
ment of metastatic melanoma if mechanisms of RA resistance
can be elucidated and exploited.
Skin is both a target and producer of 1,25(OH)2D3, the seco-
steroid ligand of VDR and regulation of melanocyte homeostasis
is a physiological role that is attributed to VDR signaling. The use
of vitamin D analogs to combat vitiligo depigmentation has been
well reviewed [183]. It is hoped that Vitamin D agonists might pro-
tect melanocyte loss in this disease through inhibition of immune
response and modulating calcium ﬂux. VDR activation may also
promote re-pigmentation processes by upregulating melanogenic
cytokines that drive pigment production. Due to insufﬁcient
knowledge on what drives the etiology of this disease, any research
implicating driver mutations is important for developing effective
therapeutics. Genomic DNA isolated from vitiligo patients, as well
as age and sex-matched controls, demonstrated the TaqI VDR poly-
morphism is a risk factor for the disease. Haplotype BsmI/ApaI/
TaqI/FokI/Cdx2 was also overrepresented in those patients [148].
The use of low-calcemic deltanoids for treatment of melanocy-
tic lesions is another potential candidate for future therapies. Sun-
light generates DNA damage within melanocytes yet also produces
anti-proliferative 1,25(OH)2D3 ligands. This physiological dichot-
omy provides endogenous regulation of melanomagenesis and
may offer directions on how to manage cutaneous melanoma. Hu-
man melanoma cell lines have been shown to posses different
expression levels of VDR and different growth inhibitory responses
to 1,25(OH)2D3. Importantly, melanoma cells demonstrate in-
creased sensitivity to deltanoids compared to normal melanocytes
[184]. Similar to some other type II NRs, a loss of VDR expression
was seen during the progression of melanocytic lesions and that
attenuated VDR signaling was linked to decreased overall survival
time [185]. Likewise, a retrospective cohort study of large numbers
of melanoma patients associated higher serum 1,25(OH)2D3 levels
with thinner presenting melanomas and improved survival from
melanoma [186]. In addition to investigations associating VDR
polymorphisms to keratinocytic pathologies, extensive studies
have shown VDR mutations as a critical contributing factor to-
wards melanoma susceptibility and outcome, in particular the
BsmI, FokI and TaqI polymorphisms [187–189]. Not all melanoma
cell lines were sensitive to 1,25(OH)2D3 treatment though. Resis-
tance to 1,25(OH)2D3 treatment may be attributed to epigenetic
mechanisms that abrogate VDR signaling in those cell lines. An in-
verse relationship has been shown to exist between VDR mRNA
expression and level of microRNA miR-125b, most likely through
posttranscriptional regulation of VDR by miR-125b interacting
with a recognition element in the 3’-UTR of human VDR mRNA.
Treatment of these cells with a DNA methyltransferase inhibitor
reduces expression of miR-125b and may prove efﬁcacious along-
side other chemical therapies [190,191]. In short, aberrant VDR sig-
naling appears to contribute signiﬁcantly to the development of
melanoma in humans and 1,25(OH)2D3 analogs may provide addi-
tional targeted chemotherapeutics in the treatment of that disease.
Due to importance of lipid metabolism in skin homeostasis,
PPAR signaling in skin has been thoroughly investigated, including
its role in melanocyte homeostasis. All PPAR isoforms are ex-
pressed in human melanocytes, though PPARc signaling appears
to be a primary possible drug target for melanoma. Two
common PPARc polymorphisms implicated in susceptibility of
Table 1
Description of pathologies associated with alteration of skin keratinocytes and melanocytes homeostasis and mechanisms inﬂuenced by type II nuclear receptor signaling.
Summary of references from the primary literature reviewed regarding keratinocyte or melanocyte-associated NR signaling. AD, atopic dermatitis; BCC, basal cell carcinoma; EPB,
epidermal permeability barrier; Hh, hedgehog; SC, stratum corneum; SCC, squamous cell carcinoma; TSLP, thymic stromal lymphopoietin; UVR, ultraviolet radiation.
Pathology Mechanism Ref. Pathology Mechanism Ref.
RXR
EPB defects Lamellar granule formation in epidermis [43] Melanoma Stage-related loss of expression [163,175]
Alopecia Follicular destruction and hair cycling defects,
epidermal hyperplasia
[86,87] Growth and invasion arrest by NR ligands [164]
AD TSLP derepression and Th2-type inﬂammation [88,90] Growth arrest by NR ligands [165,166,172]
Psoriasis Stage-related loss of expression [89] Keratinocyte-derived paracrine effects in
melanomagenesis
[130,167,168]
SCC Cell-autonomous suppression of epidermal
tumorigenesis and progression
[130]
Stage-related loss of expression [136]
RAR
EPB defects Lamellar granules formation in epidermis [43] Melanoma Stage-related loss of expression [163,175]
Aging UVR-induced loss of expression [131,132] Epigenetic silencing of RARb [176]
AD TSLP derepression and Th2-type inﬂammation [90] Anti-proliferative and pro-differentiative
properties
[165,169,172,174]
Psoriasis Negative gene regulation via retinoids [140] Induction of apoptosis by retinoids [170,171]
SCC Stage-related loss of expression induces
malignant progression
[136,138] Regulation of cell surface receptors [180,182]
BCC Anti-proliferative and pro-apoptotic effects of
retinoids
[141] Modulates HLA-DR expression on melanoma [169]
BCC Tumor suppressor activities of basal RAR
signaling
[142] Increase in chemokine and IFNb secretion [179]
VDR
EPB defects VDR genetic network linked to EPB function,
inﬂammation
[58] Vitiligo VDR polymorphisms linked to vitiligo
susceptibility
[148]
Alopecia VDR/ mice display progressive hair loss [55] VDR targets the epidermal melanin unit [183]
Alopecia VDR drives mammalian hair cycle through gene
repression
[62] Melanoma Stage-related loss of expression of VDR [185,186]
AD TSLP derepression and Th2-type inﬂammation [58,90] miRNA associated epigenetic silencing [190,191]
AD Low-calcemic VDR agonist improves allergen-
induced eczema
[91] Anti-proliferative and pro-differentiative
properties of vitamin D analogs
[184]
SCC VDR polymorphisms linked to SCC
development, tumor susceptibility
[58,143,147] VDR polymorphisms linked to melanoma
development
[187–189]
SCC VDR/mice susceptible to carcinogen-induced
SCC through Hh pathway
[149,150]
BCC VDR polymorphisms linked to BCC
development
[146,147]
BCC VDR/mice susceptible to carcinogen-induced
BCC through Hh pathway
[150]
PPAR
EPB
formation
Lamellar granules formation [43] Melanoma Growth and invasion arrest by PPAR ligands [164]
PPAR agonists regulate involucrin and CD36
expression
[65] Growth arrest by PPAR, RAR and RXR agonists [165,166]
PPARb/d is required for EPB homeostasis [100] PPAR-mediated downregulation of b-catenin
downregulates MITF
[194]
Activators stimulates lipid synthesis and [107] Growth arrest and induction of apoptosis by [195]
(continued on next page)
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Pathology Mechanism Ref. Pathology Mechanism Ref.
processing PPARc ligands
Regulate expression of cholesterol and water
transporters
[109–111] PPARc agonists inhibit proliferation and
modulate Wnt/b-catenin mediated signaling
[196]
Alopecia PPARc ablation in hair follicles displays a
scarring alopecia phenotype
[69]
Aging PPARd/c provides resistance to UV-induced
cellular senescence through PTEN upregulation
[103]
PPARc is necessary for production of UV-
induced epidermal prostaglandins
[104]
AD PPAR regulates IL-2-mediated Treg induction [92]
PPAR negatively regulates skin inﬂammation
through TH1 and TH2 responses
[93]
PPAR agonists as therapy in murine AD models [94,95,117]
Psoriasis Activation of epidermal PPAR linked to psoriatic
gene regulation
[96,97]
Inhibition of PPAR signaling as therapy for
psoriasis
[98]
SCC Loss of expression induces malignant
progression
[130]
Inhibition of PPAR signaling as therapy for SCC [152,153]
BCC Loss of expression during progression [130]
LXR
EPB defects LXR/AP-1 crosstalk in lipid production and
barrier formation
[72] Vitiligo Increased expression in vitiligo perilesional skin [201]
EPB
formation
Acidiﬁcation of SC [106] Melanoma LXR ligands inhibit CCR7 expression on maturing
DCs and their migration to lymphoid organs
[202]
EPB
formation
Activators stimulates lipid synthesis and
processing
[107]
EPB
formation
Regulate expression of cholesterol and water
transporters
[108–111]
Aging Phenotype of chronically aged skin [114]
Aging Cigarette smoke inhibits LXR translocation [115]
AD LXR agonists display anti-inﬂammatory effects [116,117]
Psoriasis Loss of LXR expression stimulates psoriatic gene
proﬁle
[118]
TR
Alopecia Hair follicles are direct targets of thyroid
hormone
[76–78]
SCC TRs inhibit tumor progression and suppress
metastasis
[154]
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risk, though it appeared that inactivating mutations do not appear
to be a signiﬁcant risk factor for the disease [192]. Recently a link
was shown between a-MSH signaling and PPARc nuclear translo-
cation that reduced proliferation rates and increased melanogene-
sis through the Pi(4,5)P2/Plcb pathway [193]. Glitazones are known
to activate PPARc and promote melanocyte differentiation. One
mechanism to induce melanocyte differentiation is through b-cate-
nin mediated upregulation of MITF levels. Phenotypic changes that
occurred in melanoma cells post-ciglitazone treatment include
dendritic morphology and increased tyrosinase functions, possibly
linked to large increases of Mitf promoter activity. b-catenin pro-
tein levels in ciglitazone-treated murine melanoma cells followed
the same trend of transient increase followed by gradual decrease
pattern as seen with MITF, suggesting that depleted levels of nucle-
ar b-catenin was inﬂuencing the downregulation of MITF activity
in these cells [194]. In addition to its pro-differentiative properties,
inhibition of proliferation was seen in melanoma cells after ciglit-
azone treatment and is also associated with induction of apoptosis
[195]. PPARc agonists regulate the WNT3A/b-catenin signaling
pathway and inhibits human melanoma cell proliferation through
direct inhibition of b-catenin activity [196]. Though PPAR functions
as a tumor suppressor at times, two studies screening large num-
bers of melanocytic lesions determined that both PPARc and
COX-2 expression was increased during progression from benign
nevi to metastatic melanoma and may indicate therapy response
levels of this disease [197,198]. That conﬂicting role of PPARc intumorigenesis has yet to be elucidated but provides an exciting
investigative target in the treatment of metastatic melanoma.
Few reports demonstrate a role of LXR activation in melano-
cytes, though known LXR target genes are important in melanocyte
biology. LXRa appears to be the predominant isoform and could
provide LXR-oriented strategies of melanoma therapy. LXRa
expression was also localized adjacent to the follicular dermal pa-
pilla, suggesting a contribution to hair follicle melanocyte activity
[199]. LXRa expression was seen in both human melanocytes and
in melanoma cells. Moreover, LXRa mRNA and protein levels were
increased in melanocytes present in the skin surrounding vitiligo
lesions compared to normal skin, suggesting LXRa is modulating
the melanocytic response to this disorder [200,201]. Interestingly,
LXRa has been linked to immunoevasion of melanoma through
inhibition of dendritic cell (DC) migration to lymphoid organs. Pro-
duction of LXR ligands from both human and mouse tumors were
shown to hinder CCR7 expression on DCs that is required for lym-
phoid homing. Conditioned media from the human melanoma cell
line MSR3 was shown to inhibit CCR7 expression in DCs, though
not affecting other aspects of DC activation. Also, the media from
MSR3, as well as from another melanoma cell line MR255, was able
to activate LXRareporter constructs, suggesting the presence of li-
gands expressed in the media. Use of the sulfotransferase enzyme
SULT2B1b, which inactivates natural oxysterols, was able to pro-
tect CCR7 inhibition from the conditioned media. Similarly, mice
receiving bone marrow transplants from an LXRa-null line demon-
strated an enhanced ability of tumor rejection [202]. Altogether,
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naling in melanocytic lesions and in melanoma primarily mediated
by LXRa. Additional studies are required to establish the receptor
functions in melanocyte homeostasis and in melanomagenesis.
Evidence for a role of TR in melanocyte biology is limited,
though thyroid-stimulating hormone expression is seen in epider-
mal melanocytes. Of note, one study involving patients with uveal
melanoma demonstrated that 60% of the cohort contained a loss of
heterozygosity in the TRb alleles in both the ciliary body and cho-
roidal melanomas [203]. Further in vivo studies are needed to
determine how TR signaling is impaired in epidermal diseases
and in skin cancer, as well as the severity of any non-autonomous
actions that affect the malignant transformation of melanocytic
cells.
6. Conclusion
RXR/NR signaling makes important contributions to both the
development and homeostasis of keratinocyte andmelanocyte biol-
ogy (Table 1). The ability of epidermal tissue to maintain a rigorous
cycle of proliferation and differentiation utilizes complex transduc-
tion pathways that rely on tight transcriptional control of key target
genes. Ligand activated regulation of gene transcription and/or
repression by type II NR heterodimers is one example of how skin
is able to continually replenish itself while at the same time inhibit-
ing neoplastic transformation. Extensive research presents a sce-
nario where type II NRs are critical tumor suppressors that
regulate the sequential differentiation of maturing keratinocytes.
With the exception of TR, which does not appear to play amajor role
in skin biology, loss of RXR/NR activity through inactivating muta-
tions or epigenetic silencing leads to hyperproliferation and im-
mune responses. Likewise, activation of NR heterodimers through
endogenous ligand binding, or exogenous topical application of syn-
thetic agonists, typically provides anti-inﬂammatory actions. Mod-
ulation of these receptors could provide supplemental therapy for
inﬂammatory skin disease that is usually treated with potent GCs.
The development of tissue speciﬁc NR ligands may provide addi-
tional relief for diseases such as psoriasis and AD that are not cur-
rently curable. RXR/VDR regulation of genes such as TSLP provides
strong drug targets that could signiﬁcantly alter themicro-environ-
mentalmilieu that drives skin inﬂammation. Abolishing keratinocy-
tic derived paracrine signaling utilized bymelanocytes and immune
cells may provide additional options in curative techniques for skin
diseases including melanoma. Overall, RXR/NR signaling has
evolved as extensive and dominant signaling networks within skin,
the largest organ and most important barrier to environmental
damages and insults. Utilizing these regulatory checkpoints through
the use of synthetic ligands will be an important focus of cutaneous
research in the immediate future.
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